Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK6097608B
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GSK6097608B is a humanized monoclonal antibody targeting CD96 (also known as TACTILE), an inhibitory checkpoint receptor expressed on T cells and Natural Killer (NK) cells. CD96 belongs to the CD226 (DNAM-1) axis and competes with the co-stimulatory receptor CD226 for binding to shared ligands, such as CD155 (PVR), on tumor cells. By antagonizing CD96, GSK6097608B is designed to block inhibitory signaling and enhance the anti-tumor activity of immune cells. Developed by GSK, the agent is currently being investigated in Phase 1 and Phase 2 clinical trials, primarily in combination with other immunotherapies like the PD-1 inhibitor dostarlimab, for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC).
- Other names
- anti-CD96 monoclonal antibodyanti-CD-96 monoclonal antibodyanti-CD 96 monoclonal antibody
02
Targets
CD96 (T-cell surface protein tactile)
Beyond the preview
Go deeper on GSK6097608B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK6097608B.